1247results about "Phosphorus organic compounds" patented technology

Among other things, the present disclosure provides oligonucleotide compositions and methods thereof. In some embodiments, oligonucleotides comprise various chemical modifications. In some embodiments, the present disclosure provides technologies useful for manufacturing oligonucleotides.

The invention relates to an organic compound, a solar cell and application thereof. The organic compound is shown as a formula (1), wherein Ar is selected from any one of substituted or unsubstituted aryl with the ring-forming atom number of 6-50, substituted or unsubstituted heteroaryl with the ring-forming atom number of 5-50, a group shown as a formula (A) and a group shown as a formula (B), Ar'is selected from an electrically neutral organic group, and L is selected from a paraffin subunit with the carbon atom number of 1-10; r1 is an oxyacid group; n1 is selected from any integer of 1-3, and m1 is selected from any integer of 1-10; or the organic compound is an oxyacid radical salt of the compound as shown in the formula (1). The organic compound not only can be used as a passivation material, but also can be used as a hole transport material, and can improve the photoelectric conversion efficiency of a solar cell when being applied to preparation of the solar cell.

The invention relates to the technical field of surfactants, and discloses a preparation method of a modified polycarboxylate surfactant and application of the modified polycarboxylate surfactant in pesticide preparations. 3-hexene-1, 6-diamine and epoxy chloropropane are used as raw materials, 1, 6-tetraglycidylamine-3-hexene is obtained through ring-opening and ring-closing reactions, 1, 6-tetraglycidylamine-3-hexene is utilized twice, and the yield of the 1, 6-tetraglycidylamine-3-hexene is increased. The preparation method comprises the following steps: sequentially reacting 2, 3, 4, 6-tetraglycidylamine-3-hexene with sodium hydrogen sulfite and phosphoric acid to obtain tetrasulfonate hexene and tetraphosphate hexene, and copolymerizing the tetrasulfonate hexene and the tetraphosphate hexene with acrylic acid and methacrylate to obtain the modified polycarboxylate surfactant. The modified polycarboxylate surfactant prepared by the preparation method disclosed by the invention has excellent dispersing performance, heat storage stability and relatively high suspension rate.

A surface treatment agent containing a hydrocarbon-terminal-group-containing compound of the following formula makes it possible to form a cured film that is exceptional in water repellency, slipperiness, dirt removability, and abrasion resistance, particularly steel wool abrasion resistance and wet abrasion resistance. (R1 is a C12-80 monovalent hydrocarbon group that includes a C12 or higher monovalent or divalent linear unsubstituted aliphatic saturated hydrocarbon group and does not contain a hydrocarbon branched structure, R2 is H, a halogen atom, a hydroxyl group, a siloxy group, an -OSi(CH3)3 group, an -OSi(C2H5)3 group, an amino group, an SH group, a monovalent hydrocarbon group, R1, -V-Z-(Y-A)m, or -Y-A, U is a single bond, C, or a trivalent or tetravalent organic group, V is a single bond or a divalent hydrocarbon group, Z is a single bond, C, Si, N, S, or a trivalent to octavalent organic group, Y is a single bond or a divalent hydrocarbon group, A is a monovalent reactive group, k is 0, 1, or 2, and m is 1-7.)

Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I):or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, L, L1, L2, L3, L4, M and n are as defined herein. Methods associated with preparation and use of such compounds are also provided.

Compounds useful as fluorescent or colored dyes are disclosed. The compounds have the following structure (I):or a stereoisomer, tautomer or salt thereof, wherein R1, R2, R3, R4, R5, L1, L2, L3, L4, M, m and n are as defined herein. Methods associated with preparation and use of such compounds are also provided.

The present invention relates to the technical field of surfactants, and discloses a preparation method of a modified polycarboxylate surfactant and its application in pesticide preparations. The present invention uses 3-hexene-1,6-diamine and epichlorohydrin as raw materials, and obtains 1,6-tetraglycidylamine-3-hexene through ring opening and ring closing reactions. 1,6-tetraglycidylamine-3-hexene is used twice to react with sodium bisulfite and phosphoric acid in sequence to obtain tetrasulfonate-based hexene and tetraphosphate-based hexene, and then the two are copolymerized with acrylic acid and methacrylate to obtain a modified polycarboxylate surfactant. The modified polycarboxylate surfactant prepared by the present invention has excellent dispersibility, heat storage stability and high suspension rate.

The present invention relates to compounds and methods useful for inhibiting the DNA polymerase IIIC enzyme. The present invention also provides pharmaceutically acceptable compositions comprising the compounds of the present invention, and methods of using the compositions in the treatment of Gram-positive bacterial infections.

The invention relates to the technical field of biological medicine, in particular to a ferroptosis inhibition type phospholipid-like material and application thereof. The ferroptosis inhibition type phospholipid-like material is one of the following structural general formulas (1)-(5). The biomimetic phospholipid-like ferroptosis inhibitor has a long retention characteristic in main positions (cell membranes, endoplasmic reticulum and other organelle membranes) of cell ferroptosis, so that the ferroptosis inhibition efficiency is remarkably improved. The novel phospholipid-like material not only can be used as an active drug molecule, but also can be used as a pharmaceutic adjuvant for constructing drug delivery carriers such as lipidosome and micelle and implant coatings, and is suitable for various administration routes such as oral administration, injection and local administration. The novel biomimetic ferroptosis inhibitor can efficiently relieve cell ferroptosis and has a wide application prospect in the field of treating or retarding ferroptosis-related diseases.

Disclosed in the present invention is a method for simultaneously preparing high-purity sphingomyelin and glycerol phosphocholine. The method comprises the following steps: 1) adding a degradation agent to a phospholipid mixture to degrade phospholipid, so as to obtain a sphingomyelin and glycerol phosphocholine mixture, and carrying out separation by means of a refining method to obtain a crude product; 2) carrying out column chromatography to obtain sphingomyelin having a purity higher than 98%; and 3) obtaining glycerol phosphocholine having a purity higher than 95% by means of a refining method; and 4) drying same to obtain a phospholipid satisfying the pharmaceutical standard. The solvent used in the present invention can be recycled and reused and is environmentally friendly, and the method has mild reaction conditions, good selectivity, low requirement for the raw material purity, and a relatively low production cost, and is beneficial to industrial mass production.

Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and / or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.

Provided herein are a class of helper lipid compounds of use in the in vivo delivery of therapeutic agents, such as nucleic acids.

Disclosed are an aluminum diethylphosphinate crystal with a low fine powder content, a preparation method therefor and use thereof in flame retardance of glass fiber-reinforced engineering plastics. In the present invention, a phosphorus-containing aluminum salt complex is used as a seed crystal and is added in a crystallization process of preparing aluminum diethylphosphinate, such that the crystallization process can be effectively regulated and controlled, aluminum diethylphosphinate crystal particles with a low fine powder content, narrow distribution and a large particle size can be obtained, and the problems that the existing aluminum diethylphosphinate powder is prone to bridging, unsmooth feeding and the like can be solved. The present application is applicable to a processing technology of halogen-free flame retardant glass fiber-reinforced engineering plastics. The prepared aluminum diethylphosphinate includes a small amount of phosphorus-containing aluminum salt complex seed crystals, and the flame retardant property of the aluminum diethylphosphinate is not affected.

Exemplary olfactory delivery scaffolds may include 1) an olfactory targeting component, stimulant, or odorant that is recognized by the olfactory nerves via, for example, a smell response, 2) a molecule with biological activity, a therapeutic component, and / or drug (sometimes collectively referred to herein as a "therapeutic component"), and 3) a linker component that links the olfactory targeting component and therapeutic component together. The olfactory delivery scaffolds may be used to deliver a molecule with biological activity and / or a therapeutic component to a subject's neurological system through the olfactory pathway and pharmaceutical compositions useful in the treatment of neurological and / or neurodegenerative diseases.

Exemplary olfactory delivery scaffolds may include 1) an olfactory targeting component, stimulant, or odorant that is recognized by the olfactory nerves via, for example, a smell response, 2) a molecule with biological activity, a therapeutic component, and / or drug (sometimes collectively referred to herein as a “therapeutic component”), and 3) a linker component that links the olfactory targeting component and therapeutic component together. The olfactory delivery scaffolds may be used to deliver a molecule with biological activity and / or a therapeutic component to a subject's neurological system through the olfactory pathway and pharmaceutical compositions useful in the treatment of neurological and / or neurodegenerative diseases.

The invention belongs to the technical field of chemical production, and particularly relates to a micro-channel phosphate ester production device. Comprising a micro-channel reactor, a horizontal pushing reactor and a microporous purification reactor, the micro-channel reactor comprises a reactor cylinder; a vertical micro-channel heat exchange tube is arranged in the barrel; a plurality of micro-channel reaction grooves are formed in the outer wall of the micro-channel heat exchange tube; the micro-channel reaction tank is communicated with the inner cavity of the reactor cylinder; the hydrogen chloride gas entrained with butanol generated by the invention is introduced into the microporous purification reactor to realize the separation of the hydrogen chloride gas and butanol; products and heat energy in the production process are recycled, so that the synthesis conversion rate of phosphorus oxychloride reaches 99%; meanwhile, the generation of reaction byproducts is reduced, and the purity of a main product is improved.

The present disclosure relates to novel small molecules, particularly, sulforaphane analogues (SFNAs) as well as αCD / SFNAs inclusion complexes and their use as lead compounds for manufacturing a medicament or a pharmaceutical composition for therapy, in particular, for treating cancer.

The invention provides an antistatic agent for fuel oil and a preparation method thereof, and belongs to the technical field of petrochemical engineering, and the preparation method comprises the following steps: S1, adding soybean lecithin and chlorosulfonic acid into dichloroethane, uniformly mixing, under the protection of nitrogen, heating and stirring for reaction, neutralizing reaction liquid, and performing rotary evaporation to obtain sulfonated soybean lecithin; the preparation method comprises the following steps: adding sulfonated soybean lecithin and ethidene diamine into absolute ethyl alcohol, then adding p-toluenesulfonic acid, heating and stirring for reaction, and carrying out reduced pressure distillation to obtain modified soybean lecithin; s2, dispersing the SiO2 particles in absolute ethyl alcohol, adding KH-550, and performing ultrasonic treatment, centrifugation and drying to obtain pretreated SiO2 particles; and uniformly mixing the modified soybean lecithin and the pretreated SiO2 particles, adding the mixture into a supercritical fluid reactor, heating and pressurizing, ultrasonically dispersing, and drying to obtain the antistatic agent. The antistatic agent has the advantages of good dispersibility, strong stability and strong antistatic capability.

The present invention provides nitroxoline prodrugs and uses thereof, specifically, the compound of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing the same, compositions containing the same, and the use of the same in the manufacture of anti-infective and anti-tumor drugs, where the definitions of each group in formula (I) are as defined in the specification. The compound of formula (I) has good water solubility for nitroxoline and pharmacokinetic parameters such as plasma concentration and half-life. The compound of formula (I) reduces the frequency of administration and is expected to be applicable to fields other than the urinary tract field.

Intermolecular interactions and molecular chain mobility are improved when a hydrocarbon-terminal-group-containing compound represented by formula (1) is used as a surface protective agent for a non-fluorine-based material, and a surface treatment agent containing the compound can form a cured coating film having excellent water repellency, slipperiness, ease of soil removal, and abrasion resistance, in particular, steel wool abrasion resistance. (R is a C1-60 monovalent hydrocarbon group, Z is a divalent connecting functional group containing at least one selected from O, N, S, and Si, Y is a C1-30 divalent hydrocarbon group, A is a monovalent reactive group, and k is 1-3.)

Disclosed herein are a quinoline derivative, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as a PI3Kα inhibitor, and a pharmaceutical composition comprising the same. Further disclosed herein is a method of treating cancer using a quinoline derivative, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as a PI3Kα inhibitor.

To provide crystals of dihydrosphingomyelin with a reduced water content, and a production method that enables the production of the crystals of dihydrosphingomyelin with a reduced water content.SOLUTION: The present invention provides a crystal of dihydrosphingomyelin represented by the following formula (1), having peaks at diffraction angles (2θ)=3.3±0.2°, 4.9±0.2°, 6.6±0.2°, 10.0±0.2°, 13.4±0.2°, 16.8±0.2°, 18.5±0.2°, 20.2±0.2°, 21.9±0.2°, and 23.7±0.2° in powder X-ray diffraction.SELECTED DRAWING: None

Disclosed herein are compounds that can be used to prepare prodrugs, methods of producing prodrugs using the compounds, and prodrugs produced by such methods. The prodrugs produced using the compounds disclosed herein are highly soluble, allowing for good oral bioavailability.

The present invention discloses therapeutic compounds capable of targeting a wide range of tumor cells. The disclosure is further directed to compositions comprising the therapeutic compounds, methods for producing the therapeutic compounds, and methods for treating cancer comprising administering the therapeutic compounds.

A compound of formula (I): A-B-C wherein A has the following formula (AA) and X1 is selected from O, S or NH; x2 is N or C-H; x3 is N or C-RA3; wherein if X1 is NH and X2 is C-H, then X3 is C-RA3; b has the formula (B-1) or (B-2); c is selected from the group consisting of optionally substituted C6-10 carbon aryl, C5-6 heteroaryl or C5-10 heterocyclyl, and their use as PCSK9 inhibitors. # imgabs0 #

[Problem] To provide: a flame retardant which has excellent flame retardancy and contains, as an active ingredient, an organic phosphoric acid compound reduced in environmental burden; a flame-retardant polyurethane resin composition containing the flame retardant; and a synthetic leather obtained using the flame-retardant polyurethane resin composition.　[Solution] A polyurethane resin composition containing a flame retardant that contains, as an active ingredient, an organophosphorus compound which is a salt obtained by reacting phytic acid with an aliphatic polyamine, preferably an aliphatic polyamine represented by R-(NH2)x (wherein R is a C2-C12 linear aliphatic hydrocarbon group and X is an integer of 2-4).　

The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids are engineered with improved stability to oxidative degradation while in storage, while retaining high transfection activity or potency in cells. These lipids are designed to be biodegradable, thus improving the tolerability of nanoparticles formed with them in vivo. In addition, targeting of these nanoparticles in a highly specific manner to dendritic cells is provided for through inclusion of antibody conjugates directed against cell surface receptors.